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Abstract
Background: Cardiovascular magnetic resonance (CMR) allows volumetric carotid plaque measurement that has
advantage over 2-dimensional ultrasound (US) intima-media thickness (IMT) in evaluating treatment response. We
tested the hypothesis that 6-month statin treatment in patients with carotid plaque will lead to plaque regression
when measured by 3 Tesla CMR but not by IMT.
Methods: Twenty-six subjects (67 ± 2 years, 7 females) with known carotid plaque (> 1.1 mm) and coronary or
cerebrovascular atherosclerotic disease underwent 3T CMR (T1, T2, proton density and time of flight sequences)
and US at baseline and following 6 months of statin therapy (6 had initiation, 7 had increase and 13 had
maintenance of statin dosing). CMR plaque volume (PV) was measured in the region 12 mm below and up to 12
mm above carotid flow divider using software. Mean posterior IMT in the same region was measured. Baseline and
6-month CMR PV and US IMT were compared. Change in lipid rich/necrotic core (LR/NC) and calcification plaque
components from CMR were related to change in PV.
Results: Low-density lipoprotein cholesterol decreased (86 ± 6 to 74 ± 4 mg/dL, p = 0.046). CMR PV decreased 5.8
± 2% (1036 ± 59 to 976 ± 65 mm
3, p = 0.018). Mean IMT was unchanged (1.12 ± 0.06 vs. 1.14 ± 0.06 mm, p = NS).
Patients with initiation or increase of statins had -8.8 ± 2.8% PV change (p = 0.001) while patients with
maintenance of statin dosing had -2.7 ± 3% change in PV (p = NS). There was circumferential heterogeneity in
CMR plaque thickness with greatest thickness in the posterior carotid artery, in the region opposite the flow
divider. Similarly there was circumferential regional difference in change of plaque thickness with significant plaque
regression in the anterior carotid region in region of the flow divider. Change in LR/NC (R = 0.62, p = 0.006) and
calcification (R = 0.45, p = 0.03) correlated with PV change.
Conclusions: Six month statin therapy in patients with carotid plaque led to reduced plaque volume by 3T
CMR, but ultrasound posterior IMT did not show any change. The heterogeneous spatial distribution of plaque
and regional differences in magnitude of plaque regression may explain the difference in findings and support
volumetric measurement of plaque. 3T CMR has potential advantage over ultrasound IMT to assess treatment
response in individuals and may allow reduced sample size, duration and cost of clinical trials of plaque
regression.
* Correspondence: raymond.migrino@gmail.com
1Department of Medicine, Marquette University, 1120 W. Wisconsin Avenue,
Wilwaukee, WI 53233, USA
Full list of author information is available at the end of the article
Migrino et al. Journal of Cardiovascular Magnetic Resonance 2011, 13:37
http://www.jcmr-online.com/content/13/1/37
© 2011 Migrino et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Carotid atherosclerotic disease is a major risk factor for
stroke [1] and a marker of systemic plaque burden [2,3].
Carotid intima-media thickness (IMT) by B-mode ultra-
sound is the current standard for carotid evaluation as
well as clinical trial endpoint. However, in multiple trials
using 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors or statins, reduction in plaque burden as mea-
sured by IMT is modest and slow [2-5] as compared to
improvement in clinical outcomes [6-8].
Unlike ultrasound IMT, cardiovascular magnetic reso-
nance (CMR) of the carotid artery allows volumetric
measurement of plaque. Carotid CMR provides reprodu-
cible measurements, excellent spatial resolution and has
been validated with histology [9-14]. A recent study
using CMR quantified regional heterogeneity in plaque
distribution related to regional wall shear stress [15],
implying the need for full volumetric measurement.
Animal and human studies show that intensive lipid
lowering can lead to rapid change in plaque burden,
decreasing as early as 9 weeks [16,17]. Using 1.5 Tesla
(T) CMR, Lee and coworkers [18] demonstrated 3.1%
reduction in carotid plaque over 3 months of statin
treatment in 24 statin-naïve acute coronary syndrome
patients. Similarly Corti and colleagues showed plaque
regression in 18 patients treated with statins for 12
months [19,20]. Unlike ultrasound IMT, carotid CMR
has been shown to detect plaque regression at an earlier
time point. 3T CMR, in contrast to 1.5T, provides
improved signal to noise ratio that can be used to
improve image quality or shorten acquisition time [21].
Having a reliable noninvasive method for early detection
of plaque regression is important for assessment of indi-
vidual response to treatment as well as to reduce sample
size and cost of clinical trials of novel therapies. To our
knowledge, carotid plaque regression using 3T CMR has
not been compared with ultrasound IMT in patients
treated with statins. We aim to test the hypothesis that
carotid plaque volume measured by 3T CMR will
decrease following 6 month statin treatment in patients
with carotid atherosclerosis and that plaque regression
will not be detected using ultrasound IMT.
Methods
Study Subjects
Twenty-six consecutive volunteers (67 ± 2 years, 7
female) with atherosclerotic disease (coronary artery dis-
ease [n = 15, 58%] or cerebrovascular disease [n = 11,
42%]) and ≥1.1 mm carotid plaque thickness (IMT) on
screening B-mode ultrasound from 1 institution were
prospectively enrolled. Informed consent was obtained
from all subjects and the study was approved by the
local Institutional Review Board. The subjects under-
went same-day CMR and ultrasound of the carotid
arteries at baseline and following 6 months of statin
treatment. Six had initiation of statin treatment, 7 had
intensification of statin treatment (these 13 subjects
comprise the statin increase group) while 13 subjects
had maintenance of statin regimen (statin maintain
group) within 2 weeks of baseline studies, as prescribed
by their care providers (Table 1). The decision on statin
dosing was based on the judgment of the primary neu-
rologist or cardiologist taking care of the patient, with a
few patients deemed to be at very high risk for a repeat
neurologic or ischemic event treated with high statin
doses (e.g. recent embolic stroke in subjects 3 and 6 in
Table 1). Subject 1 was a participant in an initial clinical
trial wherein she was started on atorvastatin 80 mg/day
following the diagnosis of moderate/severe carotid artery
disease. Baseline and 6-month lipid profile and high sen-
sitivity C-reactive proteins were obtained using standard
laboratory methods.
Magnetic Resonance Imaging
CMR was performed using a 3T General Electric scan-
ner (Chalfont St. Giles, UK) and 4-channel carotid sur-
face coil (Clinical MR Solutions, Brookfield, WI) at
baseline and 6 months. A custom-built foam head/neck
holder reduced head mobility to replicate positioning
together with the built-in midline laser localizer. An
oblique sagittal spin echo image of the index carotid
artery (the artery with the most plaque burden; analyses
were performed only on index arteries) was used to
determine flow-divider position; images were obtained ±
12 mm from the flow divider (Figure 1). Multicontrast
imaging was performed using axial T1 (repetition time-
TR, 800 ms, echo time-TE, minimum, inversion time-TI
650 ms), T2 (TR-4000 ms, TE-50 ms, TI-250 ms), pro-
ton-density (PD, TR-4000 ms, TE-minimum, TI-250
ms) spin echo and time-of-flight (TOF, TR-20 ms, TE-
minimum) gradient echo sequences (2 mm slice thick-
ness, spatial resolution 0.31-0.62 × 0.31-0.62 × 2 mm),
similar to previous studies [11].
CMR Plaque Volume Quantification
T1/T2/PD/TOF CMR images of the index artery were
simultaneously displayed on the monitor as previously
described [15]. Using software (MR-Plaqueview, VP
Diagnostics, Seattle WA), a single reader blind to sub-
ject identity and study order measured plaque volume
(PV). The adventitial/luminal borders were traced and
the area in between multiplied by slice thickness to
obtain PV; the sum for all 12 slices comprised CMR PV.
Tracing was initially performed from T1-weighted
images but software then allowed simultaneous viewing
of luminal and adventitial tracings in all 4 contrast
weightings (T1, T2, PD and TOF) in 4 contiguous
panels on the computer screen. The tracings could then
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Treatment Groups Age (year)/
Gender
Baseline Treatment (mg) Treatment During Study (mg)
A. Statin Increase:
Initiation
1 79/F none atorvastatin 80
2 72/M none simvastatin 20
3 68/F none atorvastatin 40
4 56/F none pravastatin 40
5 86/M none atorvastatin 20
6 46/M none rosuvastatin 40
Statin Increase
7 58/M atorvastatin 10 atorvastatin 80
8 72/F simvastatin 10 atorvastatin 80
9 87/M lovastatin 40 atorvastatin 80
10 61/M simvastatin 40 simvastatin 80
11 73/M pravastatin 80 atorvastatin 80
12 65/M atorvastatin 10 atorvastatin 40
13 66/M simvastatin 20 simvastatin 40
B. Statin Maintain
14 62/M atorvastatin 40 simvastatin 20
15 61/M atorvastatin 10 simvastatin 20
16 71/M lovastatin 40 lovastatin 40
17 64/M simvastatin 80 simvastatin 80
18 57/M simvastatin 40 (noncompliant with prescribed
treatment)
simvastatin 40 (noncompliant with prescribed
treatment)
19 71/M simvastatin 5 simvastatin 5
20 63/M Ezetimibe 10/simvastatin 20 Ezetimibe 10/simvastatin 20
21 56/F simvastatin 10 simvastatin10
22 65/M atorvastatin 10 atorvastatin 10
23 82/M simvastatin 20 simvastatin 20
24 60/M simvastatin 20 simvastatin 20
25 81/F atorvastatin 10 atorvastatin 10
26 61/M pravastatin 40 pravastatin 40
Figure 1 Ultrasound and CMR images.A .B - m o d eu l t r a s o u n do ft h ec o m m o nc a r o t i da r t e ry demonstrating plaque. Automated software
detection is used to measure mean posterior IMT. B. Oblique sagittal spin echo of the carotid artery showing the reference flow divider (white
arrow). C. Multicontrast CMR T1/T2/proton density spin echo and time of flight gradient echo images of the same axial slice. Luminal/adventitial
borders are outlined to measure plaque area/volume.
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borders based on all 4 contrast images. The software
also automatically delineates plaque components based
on contrast characteristics using an automatic classifier
(morphology-enhanced probabilistic plaque segmenta-
tion algorithm) [10,11,22]. Plaque composition from
1.5T CMR images derived using the software has been
validated to correlate with histology while results on
1.5T correlated highly with 3T imaging [10,11]. The
volume of lipid-rich necrotic core (LR/NC) and calcifi-
cation components were measured and compared
between baseline and 6-months and the changes were
correlated with change of plaque volume.
From 52 carotid scans, 13 were randomly chosen and
reanalyzed in blinded fashion to obtain intraobserver
variability. The coefficient of variability was 5.3%, com-
parable to published intraobserver values for both 1.5T
and 3T CMR of 6.4-7.7% [13,14].
For circumferential plaque distribution, the carotid
luminal and adventitial tracings were imported into
M A T L A B ,a sp r e v i o u s l yp u b l i s h e d[ 1 5 ] .T h ea r t e r yw a s
divided into 6 non-overlapping circumferential regions
with 360 (or 0) degree arbitrarily selected as the most
medial point in a standard axial slice with angular desig-
nation proceeding anterolaterally. The software provided
measurements for the maximum thickness of each cir-
cumferential region, and the average for all slices calcu-
lated and compared. The investigators were meticulous
in ensuring as similar as methodologically possible head
positioning between baseline and 6-month scans. This
was accomplished by the specialized design of the caro-
tid coil that had custom-built head rest and neck sup-
port that minimized variations in three-dimensional
head positioning when the center of the nose and phil-
trum of the subject are perfectly aligned with the mid-
line laser localizer. Because of the absence of accepted
convention for designating circumferential regions, the
most medial portion of the carotid artery (an easily
identifiable point) was arbitrarily chosen as correspond-
ing to 360 (or 0) degree.
Ultrasound
Carotid B-mode ultrasound was performed using a Phi-
lips iE33 ultrasound (Philips Medical Systems, Andover,
MD) and L11-3 linear transducer by a qualified and
experienced sonographer. Measurements were per-
formed at the R wave of the electrocardiogram. The
common carotid artery, bifurcation and internal carotid
arteries were imaged on long axis at baseline and 6
months. To replicate baseline view, a Meijer Arc (Meyer
Medical Ultrasound, The Netherlands) was used. The
head was rotated 45° to the contralateral side with the
transducer placed 45° from midline. The sonographer
had visual access to baseline images (separate screen)
while obtaining 6-month images to ensure consistency
and replication of baseline views.
IMT was measured using automated methods (QLab
IMT Quantification Software, Philips Medical Systems,
Andover, MD, Figure 1). Edge-detection algorithm
determined the intima-media interfaces and provided
graphic display superimposed on the image. Manual
editing was performed if needed but was kept to a mini-
mum. The average of the mean posterior IMT of the
common carotid/bifurcation/internal carotid artery in
10-mm segments was used for analysis, similar to
ENHANCE trial method [23].
Statistical Analyses
Data are expressed as mean ± standard error of mean.
Baseline and 6-month variables were compared using
paired Student’s t-test. Circumferential plaque thickness
was analyzed using repeated measures analysis of var-
iance with region and time as covariates (Sigmastat 3.5,
Systat Software, Richmond CA); pairwise comparison
used Holm-Sidak method. Intraobserver variability was
determined using coefficient of variability (standard
deviation of difference in PV between two measure-
ments over mean of PV*100%), similar to prior studies
[24]. Correlation analysis was performed using Pearson
correlation. Significant p-value was < 0.05.
Results
Following 6 month statin treatment, there was an overall
reduction of 14% and 9% decrease in LDL and total cho-
lesterol, respectively, with greater decrease in the statin
increase group compared to the statin maintain group
(Table 2). At 6 months, mean LDL cholesterol was 74 ±
4 mg/dL. There was no change in HDL cholesterol or
C-reactive protein.
There was a 5.8 ± 2% reduction in CMR plaque
volume overall (baseline versus 6-month: 1036 ± 59 ver-
sus 976 ± 65 mm
3,p=0 . 0 1 8 ,F i g u r e2 ) .T h es t a t i n
increase group had 8.8 ± 2.8% reduction in plaque
volume (979 ± 38 versus 889 ± 39 mm
3, p = 0.001)
while the statin maintain group had a nonsignificant
change of -2.7 ± 3% in plaque volume (1094 ± 112 ver-
sus 1064 ± 123 mm
3, p = NS, Figure 2). In contrast,
ultrasound IMT showed a nonsignificant +3 ± 3%
change overall (1.12 ± 0.06 versus 1.14 ± 0.06 mm, p =
NS); the same was true for both statin increase (1.19 ±
0.08 versus 1.21 ± 0.09 mm, p = NS) and maintain
groups (1.04 ± 0.09 versus 1.08 ± 0.09 mm, p = NS, Fig-
ure 3).
In the statin increase group, 11/13 (85%) had reduced
plaque volume while 9/13 (69%) had reduced plaque
volume in the statin maintain group (Figure 4).
Using software, plaque composition was analyzed.
There was a correlation between percent plaque volume
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in LR/NC volume (R = 0.62, p = 0.006) with more mod-
est correlation with percent change in calcification
volume (R = 0.45, p = 0.03). Overall, average percent
LR/NC volume change was -2.3 ± 10% (baseline versus
6-month volume: 155.4 ± 22 versus 150.6 ± 26 mm
3,p
= NS), with statin increase group changing -18.1 ± 14%
(154.7 ± 26 versus 124.3 ± 24 mm
3,p=N S )a n ds t a t i n
maintain group changing 13.4 ± 12% (156.2 ± 37 versus
177 ± 47 mm
3, p = NS). Overall average percent calcifi-
cation volume change was -13.1 ± 12% (90.3 ± 15 versus
86.5 ± 23 mm
3, p = NS).
There was circumferential heterogeneity in CMR pla-
que thickness with greatest thickness in the posterior
carotid artery, in the region opposite the flow divider
(241-360 degrees) (Figure 5). Similarly there was
circumferential regional difference in change of plaque
thickness with significant plaque regression in the ante-
rior carotid region in region of the flow divider (61-120
degrees) overall (Figure 5B), and in the same region as
well as 301-360 degrees in the statin increase group
(Figure 5C). There was significant reduction in plaque
thickness in statin increase group (-7.1 ± 3.6%, p =
0.016) but not in the statin maintain group (2.4 ± 5%, p
= NS). There was no significant reduction in CMR pla-
que thickness when both groups are combined (-2.4 ±
2.5%, p = NS).
Discussion
We report the following novel findings: in patients with
coronary/cerebrovascular disease and carotid athero-
sclerosis, 6 month statin therapy led to reduced plaque
volume using 3T CMR. However, there was no reduc-
tion in ultrasound posterior IMT. CMR plaque regres-
sion was greater in subjects who had initiation or
increase of statins. There was circumferential regional
heterogeneity in plaque thickness and regional heteroge-
neity in plaque regression. Important implications of
this study include demonstrating the ability to measure
plaque regression on a short term basis using high field
CMR that will be relevant for following individual
patients, or potentially reducing the cost, sample size
and duration of clinical trials through the use of a reli-
able outcome marker. The study points to the need for
volumetric measurement of carotid plaque.
Measures of Plaque Regression
Carotid IMT as a measure of plaque burden is strongly
associated with increased risk for development of coron-
ary heart disease in both men and women [25,26]. Lipid
lowering therapy using statins have consistently demon-
strated ~25% reduction in major cardiovascular events
in patients with stable atherosclerotic disease [7,8,27]. In
high risk patients with acute coronary syndrome, initia-
tion of statin therapy reduced major adverse
Table 2 Lipid and high sensitivity C-reactive protein
values
Group Laboratory Value Baseline 6-months p-value
Overall Total cholesterol 161 ± 7 146 ± 5 0.04
LDL 86 ± 6 74 ± 4 0.046
HDL 44 ± 2 44 ± 2 NS
Triglyceride 149 ± 17 138 ± 13 NS
hsCRP 2.2 ± 0.5 2 ± 0.4 NS
Statin Increase Total cholesterol 175 ± 10 142 ± 6 0.002
LDL 96 ± 8 73 ± 7 0.014
HDL 42 ± 2 44 ± 2 NS
Triglyceride 161 ± 22 123 ± 10 NS
hsCRP 2.3 ± 0.7 1.8 ± 0.5 NS
Statin Maintain Total cholesterol 146 ± 8 129 ± 8 NS
LDL 77 ± 9 62 ± 6 NS
HDL 45 ± 4 43 ± 3 NS
Triglyceride 136 ± 27 120 ± 24 NS
hsCRP 2.2 ± 0.8 2.3 ± 0.8 NS
HDL-high density lipoprotein cholesterol, hsCRP-high sensitivity C-reactive
protein, LDL-low density lipoprotein cholesterol
Figure 2 CMR Plaque volume.A .A l ls u b j e c t s ,B .S t a t i ni n c r e a s eg r o u p ,C .S t a t i nm a i n t a i ng r o u p .O v e r a l lt h e r ew a sr e d u c t i o ni nC M RP V .
Reduction was significant only in the statin increase group.
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Page 5 of 10cardiovascular events as early as 4-16 weeks [28,29]. In
contrast, carotid IMT shows relatively slow reduction in
plaque burden even after 1-2 years of high dose statin
treatment [2-5,30] while some studies even showed
absence of plaque regression by IMT, especially in lower
risk subjects [30-33]. The ENHANCE trial showed that
despite 56% reduction in LDL cholesterol, 2-year treat-
ment with ezetimibe/simvastatin failed to show plaque
regression by IMT [23]. The recent ARBITER 6-HALTS
study showed lack of IMT regression in ezetimibe/statin
treated patients after 14 months despite 21% reduction
in LDL cholesterol, while showing IMT regression in
niacin/statin treated patients [34]. Dissociation between
significant reductions in cardiovascular events despite
lack of carotid IMT regression with rosuvastatin in the
JUPITER trial [32,35] points to the potential weakness
of change in carotid IMT as a surrogate marker for clin-
ical cardiovascular events [36].
Animal and human studies clearly demonstrate that
aggressive lipid lowering can lead to measurable reduc-
tion in plaque volume in a short time period of as early
as 6-9 weeks [16,17] suggesting that the temporal gap
between plaque burden regression and clinical benefit
may not be as large as carotid IMT studies suggest.
Carotid CMR provides distinct advantages over carotid
IMT in the evaluation of carotid plaque burden. In
Figure 3 Ultrasound IMT. A. All subjects, B. statin increase group, C. statin maintain group. There was no significant change from baseline-6
months.
Figure 4 CMR plaque volume reduction. A. Statin increase group (red represents statin naïve subjects, black represents statin intensification
subjects), B. statin maintain group. Blue line represents mean for the group.
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ment, CMR allows full volumetric measurement of pla-
que burden. CMR has been utilized to assess carotid
plaque regression following statin treatment using 1.5
Tesla systems [9,18-20]. Carotid CMR is associated with
high spatial resolution, excellent interstudy, interobser-
ver and intraobserver variability and has been directly
validated with histology [9-14,18]. Corti and coworkers
[19,20] demonstrated measurable reduction in carotid
plaque after 12 months of statin treatment. In patients
with known coronary artery disease who were statin
naïve, Lee and coworkers showed that aggressive lipid
lowering to LDL cholesterol levels of ~70 mg/dL (levels
comparable with the current study) with various statins
was associated with measurable reduction in carotid pla-
que (-3.1%) as early as 3 months of treatment using 1.5
Tesla carotid CMR, and this was associated with parallel
improvement in brachial endothelial function [18]. Our
study using 3T CMR showed results consistent with
their findings. We demonstrate 5.8% PV reduction in
statin-treated atherosclerotic patients leading to LDL
cholesterol levels ~74 mg/dL. Unlike the previous study,
however, only 6/26 subjects were statin-naïve (7 patients
had intensified dosing and 13 had dose maintenance).
Furthermore, our cohort’sb a s e l i n eL D Lw a s8 6v e r s u s
112 mg/dL for the prior study. A unique aspect of our
study is demonstrating the gradient of plaque regression
in established atherosclerotic patients with intensified
versus stable dosing. The reduction of PV in the statin-
increase group was seen in 11 of 13 subjects (with 1
patient without change in PV). This finding is consistent
with ASAP and ASAP extension studies [5,37] where it
was demonstrated that patients treated with atorvastatin
80 mg/day had IMT reduction over 2 years versus pro-
gression in those treated with simvastatin 40 mg/day.
After 2 years, those taking atorvastatin was maintained
on the treatment while those taking simvastatin was
switched to atorvastatin 80 mg/day. The group main-
tained on atorvastatin showed no further reduction in
IMT while the simvastatin group who had intensified
treatment showed reduction in IMT; at 4 years, there
was no difference in IMT between the two groups.
A novel contribution of this study is the direct com-
parison of carotid plaque change using 3T CMR versus
ultrasound IMT. It is important to note that CMR PV
(a 3-dimensional measurement, in mm
3,a n dt h a t
includes adventitia) is not directly comparable to IMT
measurement derived from 2-dimensional images (in
mm and excludes adventitia). So the important compari-
son is not the magnitude but rather the direction of
change between the two measurements. Whereas CMR
PV decreased by 5.8% at 6 months, there was a non-sig-
nificant change of +3% in IMT. Our results demonstrate
that change of plaque burden using IMT is not concor-
dant with volumetric change assessed by CMR.
Change in Plaque Composition
There was significant correlation in plaque volume
regression and reduction in lipid rich/necrotic plaque
volume, and a more modest correlation with reduction
Figure 5 Circumferential plaque distribution. A. T1 images showing circumferential heterogeneity in plaque thickness. Angular designation is
shown in the first image, with the most medial point arbitrarily designated as 360 degrees. B-D. Regional plaque thickness on CMR at baseline
and 6 months. Note significant regional variation in plaque thickness (+p < 0.05 versus 241-300 degrees at both 0 and 6 month periods, #p <
0.05 versus 301-360 degrees at both 0 and 6 month periods) with greater plaque thickness at 241-300 and 301-360 degree regions. In all
subjects, significant change in plaque thickness was only seen in 61-120 degree region (B); in statin increase patients, significant change was
seen in 61-120 and 301-360 degree regions (C). There was no significant regional change in thickness in statin maintain patients (D).
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deling involves parallel reduction in gross volume as
well as plaque components. Importantly, the changes in
lipid rich/necrotic plaque and calcification volumes did
not reach statistical significance, unlike plaque volume,
suggesting that using plaque component change as an
endpoint in therapeutic trials will require greater sample
size than plaque volume change. Our results are consis-
tent with the analysis of Saam, et al. [38] where mea-
surement error was 1.9 times for lipid rich/necrotic core
assessment than for plaque volume, hence requiring a
larger sample size to be able to detect similar degree of
change induced by a therapeutic intervention.
Regional Heterogeneity in Plaque Burden
The difference between CMR PV and IMT change may
lie in an important observation of circumferential het-
erogeneity in plaque distribution, a finding described by
others [39]. There is more plaque in the carotid bifurca-
tion, in the region opposite the flow divider (241-360
degree region) [15]. Posterior IMT, a region routinely
used to measure plaque in clinical trials [23], captures
the region with highest plaque burden. However, follow-
ing statin treatment, we observed non-uniform circum-
ferential plaque regression, with significant reduction
only in the region of the flow divider (61-120 degrees),
located anteriorly in an area not captured by posterior
IMT measurement, and in some (301-360 degrees) but
not all posterior regions. The inability of ultrasound to
fully capture regional plaque burden change may explain
the limitation of IMT to reliably follow up short-term
plaque regression.
Our data on regional plaque thickness change on 26
subjects (Figure 5B) remain generally consistent with
initial data on 8 subjects (5 statin increase and 3 statin
maintain) that we previously reported [15]. With more
subjects, however, we now demonstrate circumferential
regional variability in plaque thickness change from
baseline to 6 months in statin increase subjects (Figure
5C) and no significant change in plaque thickness in sta-
tin maintain subjects. This demonstrates the potential
peril of using maximum plaque thickness in serial eva-
luation of plaque regression as even regions with great-
est plaque thickness and whose posterior locations make
them ideal for ultrasound IMT studies (241-300 and
301-360 degrees) show variation in change in plaque
thickness. This again highlights the value and superiority
of volumetric assessment of plaque. Of note in statin
increase subjects, as shown in Figure 5C, there was sig-
nificant reduction in plaque thickness from 0 to 6
months at 61-120 degrees, a region of relative low pla-
que burden, as well as 301-360 degrees, a region of rela-
tive high plaque burden, suggesting that the relationship
between regional plaque remodeling and local
hemodynamic forces (e.g. wall shear stress) may be
more complex than we initially reported [15], and
deserve further investigation. Our data on regional pla-
que thickness change are not directly comparable to the
analysis performed by Corti, et al. [19] where they
showed significant difference in carotid maximum pla-
que thickness but not in minimum thickness at baseline
and 12 months of simvastatin treatment, since their
measurements did not include circumferential regional
determination of plaque thickness, hence regions of
maximum and minimum thickness may not be exactly
the same at 0 and 12 months.
If our results are validated in a larger series, there are
important clinical implications. Our study reinforces the
previous observations [18,24] that CMR can reliably
detect change in plaque burden within a short time per-
iod (6 months), but which ultrasound IMT is not able
to do. For an individual patient, this provides a novel
method of assessing response to treatment that is mea-
surable in the short term, allowing early titration of
treatment. From a research standpoint, the findings
point to the limitations of ultrasound IMT as an end-
point to assess therapeutic efficacy. Carotid CMR might
allow earlier detection of treatment efficacy of novel
treatments, and because of the excellent interstudy,
interobserver and intraobserver variability profile [9,18],
might require a smaller sample size to detect treatment
effects, potentially leading to cost-effective clinical trials.
Limitations
There are several important study limitations. The sam-
ple size is small and the study needs to be validated in a
larger series of patients. The import of our findings
should therefore be construed as hypothesis-generating
and not conclusive. Despite the small size, however, the
results are consistent with results obtained by prior
investigators using 1.5T CMR with similar sample size
[18,24]. Statins are generally believed to have similar
class effect and the clinical efficacy is related to degree
of LDL cholesterol lowering rather than to the specific
type of statin used in multiple randomized clinical trials
[40]. Despite this, however, another important study
limitation is the variable statin dosing and regimen. The
baseline differences in treatment (including some being
statin naïve and some on statins) limit data interpreta-
tion. Although meticulous care was expended to repli-
cate head positioning, subtle variation in head and
carotid position can affect the measurements and may
be minimized but not totally avoided.
Conclusions
Six month statin therapy in patients with carotid plaque
led to reduced plaque volume as measured by 3T CMR,
whereas ultrasound posterior IMT did not show any
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Page 8 of 10change. The heterogeneous spatial distribution of plaque
and regional differences in magnitude of plaque regres-
sion may explain the difference in findings and support
volumetric measurement of plaque. 3T CMR has poten-
tial advantage over ultrasound IMT to assess treatment
response in individuals and may allow reduced sample
size, duration and cost of clinical trials of plaque
regression.
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